Trial Profile
This is an Open Label Study to Evaluate the Efficacy of Intravitreal Aflibercept Injection 2mg in Patients With a Persistent FVPED Despite at Least 6 Consecutive Injections With Ranibizumab 0.5 mg
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 23 Jul 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Retinal detachment
- Focus Therapeutic Use
- Acronyms EVER
- 12 Jul 2018 Status has been changed to withdrawn prior to enrolment.
- 12 Sep 2014 New trial record